EZH2 as the catalytic subunit of polycomb repressive complex 2 (PRC2) represses target genes by H3K27me318, of which the highly activated mutations frequently locate in the early stages of cancer, suggesting a role for activated PRC2 cancer drivers. This evidence concerns the gene EZH2 and cancer.